Loading news...
NEOS Investment Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 82.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,051 shares of the company's stock after buying an additional 13,599 shares during the period. NEOS Investment Management
Fifth Third Bancorp raised its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 23.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,374 shares of the company's stock after acquiring an additional 1,392 shares during the period. Fifth Third
Baron Partners Fund increased 19.07% (Institutional Shares), exceeding its benchmark, the Russell Midcap Growth Index. SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Shares of global hotelier Hyatt Hotels Corporation increased during the quarter as the company delivered strong revenue per available room and unit growth despite concerns around a weakening macroeconomic environment.
IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) and Vaso (OTCMKTS:VASO - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation. Profitability This table compares IDEXX Laboratories and Vaso's net
Assetmark Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 20.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,251 shares of the company's stock after selling 13,534 shares during the period. Assetmark Inc. owned about 0.06%
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 26, 9:55 am – 10:30 am EST – Mike Lane, Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the virtual BofA Securities Anima.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Candriam S.C.A. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 70.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,975 shares of the company's stock after selling 56,053 shares during the period. Candriam S.C.A.'s holdings in IDEXX Laboratories were
Oppenheimer Asset Management Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 10.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,170 shares of the company's stock after selling 3,458 shares during the period. Oppenheimer
IQ EQ FUND MANAGEMENT IRELAND Ltd decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 59.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,381 shares of the company's stock after selling 1,995 shares during the quarter.
Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
IDEXX Laboratories Inc. (NASDAQ: IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.
Y Intercept Hong Kong Ltd bought a new position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the third quarter, according to its most recent filing with the SEC. The firm bought 1,047 shares of the company's stock, valued at approximately $669,000. Other large investors also recently bought and sold shares of the company.
Dow Jones gains 500 points. Markets digest Trump's Fed chair nomination. CNN Money Fear and Greed index shows improvement.
Revenue Growth: 14% increase as reported and 12% organic growth in Q4 2025.CAG Diagnostics Recurring Revenue: 10% organic growth in Q4 2025.EPS: $3.08 in Q4 20
Major stock indexes surged Monday to begin a new month of trading, with the Dow Jones Industrial Average adding 500 points and the S&P 500 poised to set a new closing record.
IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
IDXX tops Q4 EPS and revenue estimates as margins expand. However, shares dip during the pre-market trading, while 2026 guidance calls for steady growth.
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.08 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.62 per share a year ago.